Obesity drugs are rapidly moving from the margins of lifestyle care to the centre of India’s pharmaceutical growth story as rising lifestyle diseases, new blockbuster launches and the looming entry of low-cost generics reshape the market. With global consultants McKinsey ranking obesity therapies alongside AI, electric vehicles and robotics as trillion-dollar opportunities by 2040, India…
Mumbai: Emcure Pharmaceuticals has announced the commercial launch of the second brand of Danish drug maker Novo Nordisk‘s popular GLP-1 weight management medication. Emcure is the first Indian company to exclusively distribute and commercialise Poviztra. Poviztra will be available at a starting price ₹8,790 for the lowest dosage for a month’s treatment of four shots….
GLP-1 Drugs Linked to Lower Cataract and Dry AMD Risk: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study. The drugmaker’s Denmark-listed shares were up 3.3%. Novo said the drug appeared safe and well tolerated, with mostly mild-to-moderate gastrointestinal side effects. The…
Mumbai: Danish drugmaker Novo Nordisk has tied up with Indian pharma company Emcure Pharma to distribute and market a second brand of its diabetes and weight-loss injection semaglutide in a bid to widen its reach in the country using the Pune-based company’s distribution channel and field force. The semaglutide brand, to be exclusively distributed and…
Just over seven months after Eli Lilly launched Mounjaro (tirzepatide) in India, the diabetes and weight-loss medicine has emerged the country’s highest selling drug, racing past top-selling legacy drugs like antibiotic Augmentin. When Mounjaro debuted in March, the market was on the cusp of a transformation – driven by consumers showing greater willingness to use…
Gates Foundation, PAHO Push to Make Mounjaro, Wegovy Affordable in Low-Income Countries We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Novo Nordisk‘s and Eli Lilly‘s blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday. Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be…
Indian firms that make active pharmaceutical ingredients, or APIs, are gearing up to supply the basic ingredient that goes in making copies of Novo Nordisk A/S’s weight-loss drugs that are losing patent protection next year in several large markets. From local giants Dr Reddy’s Laboratories Ltd. to suppliers like Macleods Pharmaceuticals Ltd., Indian firms are…
Novo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat a wide range of health conditions linked to obesity, as it has already begun doing with its blockbuster drug Wegovy. The Danish drugmaker aims to build evidence across both severe and more common obesity-related conditions that affect patients’ daily lives,…